Lucid Diagnostics Inc.

What they do

Lucid markets EsoGuard, a bisulfite-converted targeted next-generation sequencing DNA assay that quantifies methylation at 31 sites on the VIM and CCNA1 genes. Samples are collected in-office in under two minutes using EsoCheck, an FDA 510(k)-cleared and CE Mark certified swallowable balloon capsule catheter that the company says provides anatomically targeted, protected sampling. The tests are based on technology licensed from Case Western Reserve University, and operations run through subsidiaries LucidDx Labs Inc. and CapNostics, LLC. The company targets the roughly 30 million U.S. individuals it says guidelines recommend for Barrett's esophagus screening.

Revenue drivers

• EsoGuard Esophageal DNA Test — The sole reported revenue line: 2Q26 EsoGuard revenue was $1.5 million on 2,770 tests processed, versus $1.2 million in 3Q25 and $1.3 million in 1Q26.
• EsoCheck Esophageal Cell Collection Device — The FDA-cleared collection device used with EsoGuard; it is not broken out as a separate revenue line in the reported results.
• Payor coverage as a volume gate — Revenue depends on reimbursement; the company cites an effective Medicare payment of $1,938 and a total addressable U.S. market it estimates at approximately $60 billion.

Recent performance

For the three months ended June 30, 2026, revenue was $1.474 million, up from $1.163 million in the prior-year quarter, and six-month revenue was $2.730 million versus $1.991 million. Cost of revenue of $1.445 million in 2Q26 was nearly equal to revenue, producing minimal gross margin. Total operating expenses were $14.275 million, including sales and marketing of $5.776 million and G&A of $5.757 million, yielding an operating loss of $12.801 million. GAAP net loss attributable to common stockholders was approximately $14.7 million, or $(0.08) per share, including a $3.0 million deemed preferred stock dividend; non-GAAP adjusted loss was approximately $10.9 million, or $(0.06) per share. Cash was $33.4 million at June 30, 2026, versus $34.7 million at December 31, 2025.

Strategy

Management says it is advancing commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard. The company secured a commercial coverage policy from Concert, a laboratory benefit manager whose client health plans can adopt the policy, and says multiple plans have already adopted it. It reported accelerated engagement with the VA and major health systems, and developed a health economic cost-effectiveness model with preliminary results showing improved clinical outcomes and cost-effectiveness. Management also cites increasing visibility to expand opportunities for broader strategic engagement.

Risks

• Going concern — The company states it has concluded there is substantial doubt about its ability to continue as a going concern, and its auditor's report includes an explanatory paragraph to that effect.
• Persistent losses and cash burn — Net loss was $58.0 million in 2025 and operating cash flow was negative $46.5 million, while 2Q26 revenue of $1.5 million was well below quarterly operating expenses of $14.3 million.
• Reimbursement and regulatory dependence — Revenue depends on payor coverage, and the company flags the risk that the FDA will cease to exercise enforcement discretion with respect to laboratory developed tests like EsoGuard.
• Dilution and parent-company obligations — The company has issued significant convertible securities, including $23.5 million of Senior Secured Convertible Notes carried at fair value as a current liability, and expects to need additional capital that may be compounded by obligations to parent PAVmed.

Outlook

Management says commercial momentum strengthened in the second quarter and recent weeks and that it is awaiting a positive draft Medicare coverage policy for EsoGuard. It points to newly secured commercial coverage, VA and health system engagement, and the health economic model as positioning the company to capitalize on EsoGuard's clinical and commercial opportunity. The primary stated near-term catalyst is the Medicare coverage decision, with broader strategic engagement framed as an objective.